Phillip Koo, MD

Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.

The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.

Drs Cookson and Sellinger discuss the remaining unmet needs in imaging for patients with prostate cancer.

The panel shares their perspectives on the transition to virtual multidisciplinary tumor boards for patients with prostate cancer after the COVID-19 pandemic.

Delving deeper into PSMA-PET results interpretation and information sharing, panelists outline the most critical information needed from radiologists and urologists on a patient’s multidisciplinary care team.

Experts share potential solutions to overcome the clinical challenges of using PSMA-PET in practice, including use of reader training programs.

Dr Cookson discusses the challenges of using PSMA-PET imaging in prostate cancer, including reimbursement and patient access.

Dr Sellinger details the range of clinical guidelines on the use of PSMA-PET imaging in prostate cancer and which he is most likely to follow.

The panel reviews clinical data and provides real-world insight on how use of PSMA-PET imaging has impacted the management of patients with prostate cancer.

Experts discuss practical considerations on selection among available PSMA-PET tracer options for prostate cancer imaging, including regional availability, scheduling, and preparation requirements.

The panel reviews the similarities and differences between the FDA-approved PSMA-PET tracer options for prostate cancer imaging.

Phillip Koo, MD, defines prostate-specific membrane antigen (PSMA) and explains the rationale for use as a target in PET-based prostate cancer imaging.

Scott Sellinger, MD, FACS, shares a historical perspective on use of conventional imaging modalities in prostate cancer.

Michael Cookson, MD, MMHC, explains the NCCN criteria used to stratify patients with clinically localized prostate cancer into risk groups.